|
1
|
Tong HH, Lambert G, Li YX, et al: Deletion
of the complement C5a receptor alleviates the severity of acute
pneumococcal otitis media following influenza A virus infection in
mice. PloS One. 9:e951602014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Courtois A, Berthou C, Guezennec J,
Boisset C and Bordron A: Exopolysaccharides isolated from
hydrothermal vent bacteria can modulate the complement system. PloS
One. 9:e949652014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wende E, Laudeley R, Bleich A, et al: The
complement anaphylatoxin C3a receptor (C3aR) contributes to the
inflammatory response in dextran sulfate sodium (DSS)-induced
colitis in mice. PloS One. 8:e622572013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Elvington M, Blichmann P, Qiao F, et al: A
novel protocol allowing oral delivery of a protein complement
inhibitor that subsequently targets to inflamed colon mucosa and
ameliorates murine colitis. Clin Exp Immunol. 500–508. 2014.
View Article : Google Scholar
|
|
5
|
Hundgeburth LC, Wunsch M, Rovituso D, et
al: The complement system contributes to the pathology of
experimental autoimmune encephalomyelitis by triggering
demyelination and modifying the antigen-specific T and B cell
response. Clin Immunol. 146:155–164. 2013. View Article : Google Scholar
|
|
6
|
Laudisi F, Spreafico R, Evrard M, et al:
Cutting edge: the NLRP3 inflammasome links complement-mediated
inflammation and IL-1β release. J Immunol. 191:1006–1010.
2013.PubMed/NCBI
|
|
7
|
Ma R, Cui Z, Hu SY, et al: The alternative
pathway of complement activation may be involved in the renal
damage of human anti-glomerular basement membrane disease. PloS
One. 9:e912502014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Osthoff M, Brown KD, Kong DC, Daniell M
and Eisen DP: Activation of the lectin pathway of complement in
experimental human keratitis with Pseudomonas aeruginosa.
Mol Vis. 20:38–45. 2014.PubMed/NCBI
|
|
9
|
Cravedi P, Leventhal J, Lakhani P, Ward
SC, Donovan MJ and Heeger PS: Immune cell-derived C3a and C5a
costimulate human T cell alloimmunity. Am J Transplant.
13:2530–2539. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van der Touw W, Cravedi P, Kwan WH,
Paz-Artal E, Merad M and Heeger PS: Cutting edge: Receptors for C3a
and C5a modulate stability of alloantigen-reactive induced
regulatory T cells. J Immunol. 190:5921–5925. 2013.PubMed/NCBI
|
|
11
|
Lara-Astiaso D, Izarra A, Estrada JC, et
al: Complement anaphylatoxins C3a and C5a induce a failing
regenerative program in cardiac resident cells. Evidence of a role
for cardiac resident stem cells other than cardiomyocyte renewal.
Springerplus. 1:632012. View Article : Google Scholar
|
|
12
|
Kanmura S, Uto H, Sato Y, et al: The
complement component C3a fragment is a potential biomarker for
hepatitis C virus-related hepatocellular carcinoma. J
Gastroenterol. 45:459–467. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Habermann JK, Roblick UJ, Luke BT, et al:
Increased serum levels of complement C3a anaphylatoxin indicate the
presence of colorectal tumors. Gastroenterology. 131:1020–1029.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stecker JR, Savage AA, Bruno JG, Garcia DM
and Koke JR: Dynamics and visualization of MCF7 adenocarcinoma cell
death by aptamer-C1q-mediated membrane attack. Nucleic Acid Ther.
22:275–282. 2012.PubMed/NCBI
|
|
15
|
Baig NA, Taylor RP, Lindorfer MA, et al:
Complement dependent cytotoxicity in chronic lymphocytic leukemia:
ofatumumab enhances alemtuzumab complement dependent cytotoxicity
and reveals cells resistant to activated complement. Leuk Lymphoma.
53:2218–2227. 2012. View Article : Google Scholar
|
|
16
|
Nitta H, Wada Y, Kawano Y, et al:
Enhancement of human cancer cell motility and invasiveness by
anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88).
Clin Cancer Res. 19:2004–2013. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Corrales L, Ajona D, Rafail S, et al:
Anaphylatoxin C5a creates a favorable microenvironment for lung
cancer progression. J Immunol. 189:4674–4683. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fosbrink M, Cudrici C, Tegla CA, et al:
Response gene to complement 32 is required for C5b-9 induced cell
cycle activation in endothelial cells. Exp Mol Pathol. 86:87–94.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vlaicu SI, Cudrici C, Ito T, et al: Role
of response gene to complement 32 in diseases. Arch Immunol Ther
Exp. 56:115–122. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Badea TC, Niculescu FI, Soane L, Shin ML
and Rus H: Molecular cloning and characterization of RGC-32, a
novel gene induced by complement activation in oligodendrocytes. J
Biol Chem. 273:26977–26981. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vlaicu SI, Tegla CA, Cudrici CD, et al:
Epigenetic modifications induced by RGC-32 in colon cancer. Exp Mol
Pathol. 88:67–76. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li F, Luo Z, Huang W, et al: Response gene
to complement 32, a novel regulator for transforming growth
factor-beta-induced smooth muscle differentiation of neural crest
cells. J Biol Chem. 282:10133–10137. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu L, Qin H, Li PY, et al: Response gene
to complement-32 enhances metastatic phenotype by mediating
transforming growth factor beta-induced epithelial-mesenchymal
transition in human pancreatic cancer cell line BxPC-3. J Exp Clin
Cancer Res. 31:292012. View Article : Google Scholar
|
|
24
|
Yunus MA, Chung LM, Chaudhry Y, Bailey D
and Goodfellow I: Development of an optimized RNA-based murine
norovirus reverse genetics system. J Virol Methods. 169:112–118.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li M, Han S, Zhang G, Wang Y and Ji Z:
Antiproliferative activity and apoptosis-inducing mechanism of
L-securinine on human breast cancer MCF-7 cells. Pharmazie.
69:217–223. 2014.PubMed/NCBI
|
|
26
|
Gong S, Tao Z, Liu X and Gan L: An
underlying prognosis predictor of hepatocellular carcinoma:
Oncoprotein 18. Biomed Rep. 2:85–88. 2014.PubMed/NCBI
|
|
27
|
Qiu W, Zhang Y, Liu X, et al: Sublytic
C5b-9 complexes induce proliferative changes of glomerular
mesangial cells in rat Thy-1 nephritis through TRAF6-mediated
PI3K-dependent Akt1 activation. J Pathol. 226:619–632. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tang H, Amara U, Tang D, Barnes MA,
McDonald C and Nagy LE: Synergistic interaction between C5a and
NOD2 signaling in the regulation of chemokine expression in RAW
264.7 macrophages. Adv Biosci Biotechnol. 4:30–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Curci C, Castellano G, Stasi A, et al:
Endothelial-to-mesenchymal transition and renal fibrosis in
ischaemia/reperfusion injury are mediated by complement
anaphylatoxins and Akt pathway. Nephrol Dial Transplant.
29:799–808. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Byler S, Goldgar S, Heerboth S, et al:
Genetic and epigenetic aspects of breast cancer progression and
therapy. Anticancer Res. 34:1071–1077. 2014.PubMed/NCBI
|
|
31
|
Faria JA, Correa NC, de Andrade C, et al:
SET domain-containing protein 4 (SETD4) is a newly identified
cytosolic and nuclear lysine methyltransferase involved in breast
cancer cell proliferation. J Cancer Sci Ther. 5:58–65. 2013.
|
|
32
|
Pei R, Wang P, Zhou Y, et al: Association
of BRCA1 K1183R polymorphism with survival in BRCA1/2-negative
Chinese familial breast cancer. Clin Lab. 60:47–53. 2014.PubMed/NCBI
|
|
33
|
Unnewehr H, Rittirsch D, Sarma JV, et al:
Changes and regulation of the C5a receptor on neutrophils during
septic shock in humans. J Immunol. 190:4215–4225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu L, Zhang Y, Duan X, et al: C3a, C5a
renal expression and their receptors are correlated to severity of
IgA nephropathy. J Clin Immunol. 34:224–232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Müller MC, Stroo I, Wouters D, et al: The
effect of C1-inhibitor in a murine model of transfusion-related
acute lung injury. Vox Sang. 107:71–75. 2014.PubMed/NCBI
|
|
36
|
Qin L, Ren Y, Chen AM, et al: Peroxisome
proliferator-activated receptor γ ligands inhibit VEGF-mediated
vasculogenic mimicry of prostate cancer through the AKT signaling
pathway. Mol Med Rep. 10:276–282. 2014.
|
|
37
|
Singel SM, Cornelius C, Zaganjor E, et al:
KIF14 promotes AKT phosphorylation and contributes to
chemoresistance in triple-negative breast cancer. Neoplasia.
16:247–256. 2014. View Article : Google Scholar : PubMed/NCBI
|
